Previous reports have suggested that bone morphogenetic protein (BMP) gene therapy could be applied for in vivo bone regeneration. However, these studies were conducted either using immunodeficient animals because of immunogenicity of adenovirus vectors, or using ex vivo gene transfer technique, which is much more difficult to handle. Adenoassociated virus (AAV) is a replication-defective virus without any association with immunogenicity and human disease. This study was conducted to investigate whether orthotopic new bone formation could be induced by in vivo gene therapy using AAV-based BMP2 vectors. To test the feasibility of this approach, we constructed an AAV vector carrying human BMP2 gene. Mouse myoblast cells (C2C12) transduced with this vector could produce and secrete biologically active BMP2 protein and induce osteogenic activity, which was confirmed by ELISA and alkaline phosphatase activity assay. For in vivo study, AAV-BMP2 vectors were directly injected into the hindlimb muscle of immunocompetent SpragueDawley rats. Significant new bone under X-ray films could be detected as early as 3 weeks postinjection. The ossification tissue was further examined by histological and immunohistochemical analysis. This study is, to our knowledge, the first to establish the feasibility of AAV-based BMP2 gene therapy for endochondral ossification in immunocompetent animals.
Introduction
Fracture repair and segmental bone defects healing are commonly attempted procedures in orthopedic surgery. Autogenous bone graft is currently the major treatment for bone repair. However, it can only be performed on a limited scale, and its harvesting can involve substantial donor site morbidity. Allograft bone has potential for antigenicity and disease transmission, and alloplastic materials have increased infection and poor biomechanical properties. Recently, bone morphogenetic proteins (BMPs) have been reported to be effective in enhancing bone deposition in a variety of animal studies. 1 Unfortunately, the large doses required, the short half-life and thus short-term bioavailability of BMPs, and the lack of a practical method for sustained delivery of these exogenous proteins have greatly limited the application of BMPs in clinical trials. Gene therapy, however, provides an alternative method for the delivery of BMP protein into tissues for either short-term or long-term expression, a capacity that may be used to maximally stimulate osteogenesis. 2 Gene therapy also allows the targeted delivery of protein to specific cells, thus increasing the efficacy of the desired protein at the specific target site. 3 So far, the most efficient vectors for gene delivery are viruses. The osteoinductive activity induced by retroviral-mediated BMP2 or BMP7 gene therapy has been demonstrated both in vitro and in vivo. 4, 5 However, retroviruses can only infect dividing cells, and these viruses also insert themselves randomly into the host genome DNA, activating a cell proto-oncogene or disrupting a tumor-suppressor gene. Therefore, retroviral gene transfer is usually applicable only in an ex vivo strategy. Currently, the most commonly used vehicle for BMP gene therapy is adenovirus (Ad) vector, because it is highly efficient at infecting both dividing and nondividing cells. First-generation Ad vectors containing BMP2 or BMP7 gene have been shown to induce osteogenesis in the thigh musculature of athymic nude rodents. 6, 7 The feasibility of ex vivo technique employing Ad-BMP2 for segmental bone defects healing has also been successfully achieved in rat model 8 . Recently, our research group also documented in vitro and in vivo osteogenic activity mediated by Ad-BMP4 gene transfer. 9 Although these studies clearly demonstrated the potential use of Ad-BMP gene therapy, the application of Ad vector is severely limited by the lack of persistent expression and by the pronounced immune response in immunocompetent animals and humans. 10 Adeno-associated virus (AAV) is a valuable vector for gene therapy 11 because it can mediate efficient long-term gene expression and can transduce a broad range of host tissues including both dividing cells and nondividing cells. 12 AAV vectors are also the only viral vector system based on a nonpathogenic and replication-defective virus. 13 More importantly, recombinant AAV contains no viral gene, and expression of genes delivered by these vectors does not activate cell-mediated immunity.
AAV vectors can therefore be directly applied to immunocompetent animals or humans. As a result, AAV vectors may offer the best gene transfer in the musculoskeletal system of all the viral and nonviral vectors tested in terms of greater safety, efficiency, and longevity.
So far, delivery of BMP gene by AAV vector has not been reported. Combining the merits of AAV and osteogenic BMP should confer another therapeutic advantage in promoting bone augmentation. Therefore, in the present study, we investigated the feasibility of human BMP2 gene transfer using this novel AAV vector. The results from our study clearly demonstrated an efficient AAV-mediated BMP2 gene delivery and an apparent therapeutic benefit in achieving in vivo new bone formation in immunocompetent Sprague-Dawley (SD) rats.
Results

Expression and secretion of BMP2 in mouse myoblast C2C12 cells
To demonstrate the gene transfer of BMP2 by the AAV vector, we transduced myoblast C2C12 cells with AAV-BMP2 at a multiplicity of infection (MOI: viral particles/ cell) of 10 6 and 0 (mock) as described in the Method section. At 24 h postinfection, BMP2 expression in the C2C12 cells was visualized by immunofluorescence staining using the monoclonal antibody against human BMP2. Under fluorescence microscopy, only those C2C12 cells infected with AAV-BMP2 showed positive BMP2 staining, and the expressed BMP2 protein was mainly located in the cytoplasm (Figure 1 ). However, uninfected C2C12 cells showed negative immunofluorescence staining ( Figure 2 ). In addition, 6 days after infection of AAV-BMP2 or AAV-enhanced green fluorescent protein (EGFP) at an MOI of 10 6 , the conditioned medium was collected for measurement of secreted BMP2 using ELISA. As shown in Figure 3 , the AAV-BMP2-infected C2C12 cells showed a significantly higher level of BMP2 protein secretion than that obtained from the AAV-EGFPinfected cells and uninfected cells.
Phenotype changes of C2C12 cells transduced with AAV vectors
At 6 days after infection of AAV-BMP2 or AAV-EGFP at an MOI of 10 6 and 0 (mock), the phenotype of C2C12 cells revealed a significant change. The uninfected myoblast C2C12 cells or those transduced with AAV-EGFP generated myogenic differentiation, as confirmed by formation of numerous multinucleated myotubes on day 6. However, myoblast C2C12 transduced with AAV-BMP2 inhibited their myotube formation, and almost all of these cells remained as unfused mononuclear round- 
Osteogenic induction activity in AAV-BMP2-infected C2C12 cells
To demonstrate the osteoinductive activity of the secreted BMP2, we measured alkaline phosphatase (ALP) activity, an important osteoblastic differentiation marker, in C2C12 cell layers on day 6 after infection ( Figure 5 ). Although there was intrinsic expression of ALP, C2C12 cells infected with AAV-BMP2 still showed a significant increase of ALP activity compared to those infected with AAV-EGFP or uninfected cells. Our results clearly indicated that, after treatment with AAV-BMP2, C2C12 cells not only stopped myogenic differentiation, but also underwent an obvious differentiation change from myoblast into osteoblast.
Radiographic examination for new bone formation
Immunocompetent SD rats were intramuscularly injected with a high-titer AAV-BMP2 (10 12 viral particles, VP), a low-titer AAV-BMP2 (5 Â 10 11 VP), AAV-EGFP (10 12 VP), and empty AAV (10 12 VP) in their hindlimbs to produce new bone. X-ray films were taken in those animals at 2, 3, 4, 5, 6, and 8 weeks postinjection. Radiographic analysis clearly detected the development of bone tissue in all the rats receiving high-titer AAV-BMP2 as early as 3 weeks postinjection. Although the intensity of new bone mass increased at 8 weeks postinjection, it was not significantly larger than that of rats at 3 weeks postinjection (Figure 6a-d) . However, at same time point, only mild ossification tissue could be detected in the rats that had received low-titer AAV-BMP2, which appears to be less than half of that obtained from the high-titer AAV group (Figure 6e ). In contrast, no radiographic evidence of bone formation was present in rats injected with either AAV-EGFP (Figure 6f ) or empty AAV (data not shown) at all time intervals.
Histological and immunohistochemical analysis for bone tissue
At 1, 3, and 8 weeks after operation, rats were killed and the newly formed bone tissues were examined by histological analysis. Standard hematoxylin-eosin staining confirmed the formation of new bone only in rats receiving AAV-BMP2. At 1 week postinjection, there was a significant accumulation of chondrocytes within the muscle tissue, which produced a loose extracellular matrix. The cartilaginous mass was surrounded by undifferentiated mesenchymal cells (Figure 7a ,b). At 3 weeks postinjection, woven bone was formed which was characterized by a well-defined perimeter of cortical bone rim with trabeculae structure, an obvious marrow cavity containing bone marrow and adipocyte-like cells. Other differentiated structures including osteocytes, osteoblasts, and osteoclasts had also developed within the bone-forming area. In addition, muscle tissue surrounding the new bone showed some fatty degeneration (Figure 7c,d ). At 8 weeks postinjection, more mature bone was formed, with an enlarged medullary cavity. The bone matrix showed a high lamellar structure, and the predominant cell type was osteocyte (Figure 7e ,f). No bone tissue structure was found in rats receiving either AAV-EGFP or PBS (data not shown). It was also noticeable that there was no mononuclear or macrophage cell infiltration, which indicated that no detectable immunological responses had taken place. Throughout AAV-BMP2 for bone formation Y Chen et al the whole experiment, all animals survived well with no apparent complications, until they were killed.
Immunohistochemical analysis with BMP2 antibody further demonstrated that delivery of AAV-BMP2 could establish a long-term gene transduction. Positive staining was seen in the cytoplasm of cells in the bone-forming area and surrounding connective tissues. At 1 week postinjection, BMP2-positive staining was mainly detected in chondrocytes within the cartilaginous matrix. There were also some positive staining cells in the closely adjacent muscles, but there was negative staining in distant muscle tissues (Figure 8a,b) . At 3 weeks postinjection, BMP2 expression mainly appeared in osteoblasts and osteoclasts within the woven bone area, and had also developed in cells in the surrounding connective tissues. However, the positive stains became much fainter as the osteoblasts matured to osteocytes (Figure 8c,d) . At 8 weeks postinjection, as the bone matrix became more mature, being characterized by a high lamellar structure, positive stains were mainly displayed in osteoblasts in some immature bone regions and in the surrounding connective tissues. No BMP2 staining had developed in highly differentiated osteocytes, the predominant cell type at this stage ( Figure  8e,f) . Moreover, it was noticeable that there was no significant decrease in the intensity of staining at 8 weeks postinjection, compared to that at 1 week postinjection. In contrast, no positive staining could be detected in the muscles injected with AAV-EGFP or empty AAV (data not shown). These results indicated that AAV-BMP2 gene transfer could efficiently mediate a long-term gene transduction in skeletal muscles for initiation of bone induction.
Discussion
Our present study clearly established the feasibility of AAV-BMP2 gene therapy for bone induction in immunocompetent animals. To the best of our knowledge, this is so far the first report in the field of AAV-mediated BMP gene transfer. Based on our results, we proposed that AAV-BMP2 for bone formation Y Chen et al in vivo AAV-BMP2 gene delivery is an efficient and safe procedure, with potential benefits for bone augmentation.
In the present study, mouse myoblast C2C12 cells transduced with recombinant AAV-BMP2 vector expressed and secreted high-level BMP2 protein in vitro. This was confirmed by immunofluorescence and ELISA analysis. Untreated or AAV-EGFP-infected myoblast C2C12 cells underwent a further myogenic differentiation characterized by formation of multinucleated myotubes on day 6 postinfection. However, cells treated with AAV-BMP2 retained an unfused mononuclear round-like or polygonal phenotype, a characteristic phenotype of osteoblasts. 16 Furthermore, AAV-BMP2-transduced cells demonstrated a significant increase of alkaline phosphatase activity, an important osteoblastic differentiation marker. Our in vitro study clearly indicated that AAV-BMP2 transduction could produce osteogenic BMP2 protein, which not only inhibited the myogenic differentiation of C2C12 cells, but also changed their differentiation pathway from a myoblast to an osteoblast type.
More importantly, the direct transfer of AAV-BMP2 into musculature of immunocompetent SD rats induced a significant bone regeneration. In the present study, radiographic data demonstrated that visible bone formation could be detected as early as 3 weeks after gene transfer. Histological examination further revealed a typical reconstructed bone structure. At 1 week postinjection, it was clearly shown that many accumulated chondrocytes and cartilaginous matrix were surrounded by a significant infiltration of undifferentiated mesenchymal cells. At 3 weeks postinjection, the loose cartilaginous matrix became calcified and formed woven bone characterized by trabeculae structure and medullary cavity in which bone marrow cells were filled. At this stage, there were also some other differentiated structures including osteoblasts, osteoclasts, and osteocytes, which indicated a bone remodeling process. After 8 weeks, the remodeled bone became more mature, with AAV-BMP2 for bone formation Y Chen et al a highly organized lamellar cortical structure, and mature osteocytes became the prominent cell type encased in lacunae in the bone matrix. These observations demonstrated that AAV-BMP2 gene delivery could activate an endochondral mechanism for in vivo bone formation.
To confirm that involvement of BMP2 expression mediated by AAV-BMP2 gene transfer is indeed responsible for bone formation, we performed immunostaining with BMP2 antibody in tissue sections. Our results indicated that BMP2 was only expressed in the whole bone-forming area and in closely adjacent muscles within injected sites, and that there was no positive staining in distant muscles. The expression was mainly located in the cytoplasm of immature osteoprogenitors including chondrocytes and osteoblasts, and no positive staining developed in highly differentiated osteocytes. Moreover, previous reports have documented that Admediated delivery could only result in transient expression of the therapeutic gene. The protein product of the gene usually becomes undetectable within 2-3 weeks. 17 In our present study, however, BMP2 expression could persist for at least 8 weeks in some immature regions without significant decrease of staining intensity. These results strongly supported the hypothesis that in vivo AAV-BMP2 gene delivery could mediate long-term BMP2 expression in immunocompetent animals, which participate in the whole in vivo endochondral ossification.
Recently, we also developed Ad-BMP2 and BMP4 vectors, and demonstrated that direct intramuscular injection of Ad-BMP2 or Ad-BMP4 could induce significant new bone formation in athymic nude rats. 9 Therefore, in a pilot study to ensure that AAV-BMP2 could provide better and safer results than Ad-BMP2, we first injected Ad-BMP2 at a dosage of 10 10 VP, an amount that could induce detectable new bone in athymic immunodeficient rats, into the muscle of immunocompetent SD rats. However, no radiographic evidence of bone formation was detected at 2, 3, 5, and 8 weeks postinjection. Histological analysis revealed only severe mononuclear infiltration within the injection site (data not shown). One animal even died at 3 days postinjection because of complications arising from immunorejection of Ad. Therefore, our pilot study confirmed that the application of Ad vector could be severely hampered because it produced an immune reaction in immuno- AAV-BMP2 for bone formation Y Chen et al competent animals. In the present study, however, direct transfer of AAV-BMP2 into immunocompetent SD rats successfully induced radiographic ossification as early as 3 weeks postinjection. Histological examination further demonstrated a typical bone remodeling structure without obvious infiltration of mononuclear cells. In addition, all rats injected with AAV-BMP2 survived well throughout the experiment without any complication. These results provided evidence that AAV-based BMP2 vectors were safer and more effective than Ad-based vectors, and could be directly applied into immunocompetent animals without initiating any immune reaction. Moreover, in combination with direct in vivo gene delivery method, our results represent a practicable, feasible, and less invasive gene therapy strategy for bone regeneration. Although our present results demonstrated a success of regional AAV-BMP2 gene therapy for bone reconstruction, many issues still need to be addressed before this novel approach can be further applied in clinical settings. One important issue is whether there is a threshold dosage of AAV-BMP2 for effective osteoinductive activity. In this study, rats injected with AAV-BMP2 at a dosage of 5 Â 10 11 VP showed very mild ossification, apparently less than half the extent of those injected with 10 12 VP. It seems that the bone volume can be increased if a higher dosage of AAV-BMP2 vectors is to be injected. Therefore, the appropriate dosage of AAV-BMP2 to be used in different orthotopic situations in future animal experiments or human settings should be further optimized. In addition, being a secreted protein, BMP2 is expected to exert its osteoinductive activity only locally in the extracellular matrix. In our present study, although the new bone became more mature at 8 weeks postinjection, being characterized by a lamellar cortical bone matrix, the size of ossification tissue showed no significant difference from that of animals at 3 weeks postinjection. This result suggested that the newly formed bone volume was relatively stable. However, over a long period of time, concerns about whether the mass of the new bone will gradually increase because of the long-term expression of BMP2 should still be addressed. Recently, it has been reported that the use of a tetracycline-inducible promoter allows effective regulation of AAV-based therapeutic IL-10 gene expression after intramuscular injection into mice model of rheumatoid arthritis. 18 Therefore, it seems that strictly regulated AAV-BMP gene therapy could be more promising for future clinical settings. Currently, our research group is also investigating whether AAV vector, modified by addition of BMP2 promoter, could result in controlled BMP gene therapy.
During the past few years, gene therapy using various viral vectors expressing a BMP gene to treat fracture repair and promote bone defect healing in animal models has attracted considerable interests. To our knowledge, our present study is the first to clearly establish the feasibility that in vivo AAV-BMP2 gene therapy could successfully mediate long-term gene transduction and induce new bone formation through endochondral mechanism in immuno-competent animals. Moreover, our results also strongly suggest that muscle tissues can successfully serve as an ideal bone substitute after injection with AAV-BMP vectors. In general, direct transfer of AAV-BMP2 into a skeletal muscle scaffold may represent a novel and feasible approach to bone regeneration, which is much more promising for treatment of fracture nonunion, segmental bone defects, spinal fusion, or other potential orthopedic applications in which bone augmentation is required.
Materials and methods
Construction of an AAV vector carrying human BMP2 gene
The recombinant AAV2 packaging plasmid, termed pAM/CAG-WPRE-BGH-polyA, was constructed by deleting all of the viral open reading frame (ORF), and introducing the chicken b-actin promoter and cytomegalovirus (CMV) enhancer, a multicloning site, and the bovine growth hormone polyadenylation signal. The expression cassette was flanked by 145 base pair inverted terminal repeats (ITRs), which contained palindromic sequences necessary in cis elements for replication of the viral genome. Vector plasmid pAM/CAG-BMP2 was constructed by cloning human BMP2 cDNA into XhoI and EcoRI sites located between two ITRs (Figure 1 ). Vectors plasmid pAM/CAG-EGFP was also constructed by inserting EGFP gene into XhoI and EcoRI sites. All plasmids for virus packaging were purified by a MaxiPrep Plasmid Preparation Kit (Qiagen, Hilden, Germany).
AAV vectors were produced using a helper virus-free system 19, 20 with some modification. Briefly, trypsinized HEK 293 cells were plated at 4 Â 10 6 cells in 150-mm culture dishes containing 20 ml Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (FBS, Gibco BRL, Gaithersburg, MD, USA), 1% penicillin/streptomycin and 1% glutamine, and incubated at 371C under 5% CO 2 for 24-48 h. After cells reach 80% confluence, each plate of 293 cells were cotransfected with 11 mg of pAM/CAG-BMP2 (or 11 mg of pAM/CAG-EGFP) and 66 mg of AAV helper plasmid pDG using the calcium phosphate co-precipitation method. After incubation at 371C for 10 h, growth medium was replaced with fresh medium and cells were further incubated for approximately 60 h. The transfected 293 cells were trypsinized, harvested by centrifugation, and resuspended in 150 mM NaCl buffer containing 20 mM Tris at pH 8.0. After two cycles of freezing and thawing followed by centrifugation, supernatants containing AAV vectors were combined and purified by HiTrap Heparin column chromatography (Sigma, St Louis, MO, USA). Peak virus fractions were collected and dialyzed against PBS supplemented with 1 mM MgSO 4 , and then concentrated by 100K-MicroSep centrifugal concentrator (Life technologies, Carlsbad, CA, USA). The AAV viral genome titer was quantified by Real-Time PCR using TaqMan (Perkin-Elmer Biosystems, Foster City, CA, USA). The recombinant AAV-EGFP was also constructed by the same procedure.
Expression of cellular BMP2 in myoblast C2C12 cells
For immunofluorescence analysis of cellular BMP2 expression, C2C12 cells were seeded at 1 Â 10 5 onto one six-well plate and cultured for 24 h in DMEM containing 10% FBS, 1% penicillin/streptomycin, and 1% glutamine. Cells were then infected with AAV-BMP2 at an MOI (viral particles/cell) of 10 6 and 0 (mock) for 24 h, washed , and 0 (mock). Control cells were exposed to AAV-EGFP at an MOI of 1 Â 10 6 (each group is composed of three wells). After 24 h, cells were rinsed with PBS and growth medium was replaced with fresh medium. At 6 days after infection, the phenotype changes of C2C12 cells were observed under conventional microscopy. To measure BMP2 secretion rate, the conditioned medium from either AAV-BMP2 (MOI of 10 6 and 0) or AAV-EGFP (MOI of 10 6 )-treated C2C12 cells was collected, and the secretion of BMP2 protein in the medium was determined by a human BMP2 ELISA Kit (R&D Systems, Inc., Minneapolis, MN, USA). For osteoblastic differentiation analysis, cell layers were rinsed with PBS and lysed by a buffer containing 50 mM Tris-HCl and 0.5% NP-40 at pH 7.5. The cellular ALP activity, an important osteoblastic differentiation marker, was determined by the pNPP hydrolysis method using the ALP Assay Kit (Upstate Biotechnology, Lake Placid, NY, USA).
In vivo gene transfer for bone formation
A total of 15 male immunocompetent SD rats aged between 5 and 7 weeks were used in this study. All animal procedures were conducted in accordance with Animal Ordinance (Chapter 340) in Hong Kong. Animals were randomly assigned into four groups. Group I contained six animals treated with high-titer AAV-BMP2 (10 12 viral particles, VP). Group II contained three animals treated with low-titer AAV-BMP2 (5 Â 10 11 VP). Group III contained three animals treated with AAV-EGFP (10 12 VP). Group IV contained three animals treated with empty AAV (10 12 VP). After the animals were adequately anesthetized with a mixture of ketamine (90 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.), a 5 mm sterile incision was made on the right hindlimbs. AAV-BMP2, AAV-EGFP, or empty AAV vectors were injected directly into the musculature with a microsyringe (Hamilton, Reno, NV, USA). One interrupted 4-0 silk suture was used to close the incision. Animals were allowed ad libitum activity, food and water after injection, and were radiographically examined at 2, 3, 4, 5, 6, and 8 weeks after operation. At 1, 3, and 8 weeks postinjection, rats were killed by administration of a fatally high dose of anesthetics for histological analysis.
The newly formed bone tissues were harvested from muscles, and fixed in 10% formalin neutral buffer solution at pH 7.4 for 2 days, and then decalcified with a mixture of 10% HCl and 0.1% ethylenediaminetetraacetic acid for another 2 days. The specimens were then dehydrated through a series of graded ethanol, infiltrated and embedded in paraffin wax. The tissues were cut into 10 mm sections, and several were stained with hematoxylin and eosin. Immunohistochemical staining was performed on other sections with a goat anti-human BMP2 polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at a dilution of 1:1000. Visualization of bound antibodies was performed using VECTASTAIN ABC Elite Kit and DAB Substrate Kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's protocol. These sections were then counterstained with hematoxylin.
